Screener
Mesa Laboratories MLAB Biopharmaceutical Development — Goodwill Foreign Currency Translation Gain Loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
FAQ
- What is Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — goodwill foreign currency translation gain loss of -$585K in Q2 2026.
- How has Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss decreased by 135.8% year-over-year, from $1.63M to -$585K.
- What does biopharmaceutical development — goodwill foreign currency translation gain loss mean?
- Reflects the impact of fluctuations in foreign exchange rates on the carrying value of goodwill denominated in currencies other than the reporting currency for the Biopharmaceutical Development segment. This metric highlights the sensitivity of the segment's intangible asset valuations to global macroeconomic volatility. It is a non-cash adjustment that impacts the balance sheet rather than operational cash flow.
Ask your AI about Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude